The influence of risperidone on cognitive functions in schizophrenia

Area of Science:

• Psychiatry
• Neuroscience
• Pharmacology

Background:

• Schizophrenia is often characterized by significant cognitive dysfunction.
• Second-generation antipsychotics (SGAs) were introduced with the expectation of improving these cognitive deficits.
• First-generation antipsychotics (FGAs) may contribute to or exacerbate cognitive impairments.

Purpose of the Study:

• To evaluate the impact of switching from first-generation antipsychotics (FGAs) to the second-generation antipsychotic (SGA) risperidone on cognitive functions in patients with schizophrenia.
• To assess changes in intelligence, abstract and concrete thinking, mental speed, attention, and short-term non-verbal memory.

Main Methods:

• A study involving 48 male schizophrenic patients aged 21-47 years.
• Patients were switched from FGAs to risperidone due to intolerance.
• Cognitive functions were assessed before the switch, one month after, and three months after switching to risperidone.

Main Results:

• A significant decrease in severe intellectual impairment was observed, dropping from 62% before the switch to 15% after one month and 8% after three months.
• Improvements were also noted in concrete and abstract thinking, mental speed, and attention.
• The study suggests these improvements may be due to the removal of FGAs and reduced anticholinergic burden.

Conclusions:

• Switching from FGAs to risperidone led to significant improvements in cognitive functioning in schizophrenic patients.
• The findings suggest a potential pro-cognitive effect of risperidone, possibly linked to reduced anticholinergic load and FGA withdrawal.
• Further research with controlled factors is recommended to confirm risperidone's direct pro-cognitive effects.